Advertisement

Topics

HiFiBiO Therapeutics buys early-stage biotech firm H-Immune Therapeutics

05:40 EDT 16 Oct 2018 | Pharmaceutical Business Review

The acquisition strengthens HiFiBiO Therapeutics’ strategic focus on identifying first-in-class targets for multiple immune cell types, as well as applying industry-leading technologies to develop diverse antibody therapeutics. Specific

The post HiFiBiO Therapeutics buys early-stage biotech firm H-Immune Therapeutics appeared first on Pharma Business review.

Original Article: HiFiBiO Therapeutics buys early-stage biotech firm H-Immune Therapeutics

NEXT ARTICLE

More From BioPortfolio on "HiFiBiO Therapeutics buys early-stage biotech firm H-Immune Therapeutics"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...